Teprotumumab: a new avenue for the management of moderate-to-severe and active Graves’ orbitopathy?
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Endocrinological Investigation"
DOI: 10.1007/s40618-017-0717-8
Abstract: discrepancy [8],because of these conflicting results, the role of rituximab for moderate-to-severe and active GO remains to be defined in larger, multicenter RCTs [9]. The recent guidelines published by the European Thyroid Association/ European Group… read more here.
Keywords: graves orbitopathy; moderate severe; receptor; active graves ... See more keywords